Financhill
Buy
63

PRLD Quote, Financials, Valuation and Earnings

Last price:
$2.44
Seasonality move :
-0.12%
Day range:
$2.21 - $2.48
52-week range:
$0.61 - $4.22
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
16.52x
P/B ratio:
2.63x
Volume:
267.2K
Avg. volume:
466.4K
1-year change:
75%
Market cap:
$154M
Revenue:
$7M
EPS (TTM):
-$1.61

Earnings Data

Next earnings date for PRLD
Mar 17
2026
Most recent earnings per share
-$0.26
Beat by $0.10
(Nov 12/2025)
Consensus Estimate
-$0.36
(Nov 12/2025)

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

PRLD Quarterly Earnings History

Date Quarter Revenue Forecast Actual Revenue Reported EPS Consensus EPS Beat/Miss
03/17/2026 Q4 $20.5M -- -- -$0.18 --
11/12/2025 Q3 -- $6.5M -$0.26 -$0.36 $0.10
08/14/2025 Q2 -- -- -$0.41 -$0.43 $0.02
05/07/2025 Q1 -- -- -$0.42 -$0.47 $0.04
03/10/2025 Q4 -- $4M -$0.52 -$0.47 -$0.05
11/06/2024 Q3 -- $3M -$0.43 -$0.46 $0.04
08/12/2024 Q2 -- -- -$0.46 -$0.43 -$0.03
05/07/2024 Q1 -- -- -$0.42 -$0.48 $0.07
02/15/2024 Q4 -- -- -$0.60 -$0.49 -$0.11
11/01/2023 Q3 -- -- -$0.45 -$0.58 $0.13
08/03/2023 Q2 -- -- -$0.54 -- --
05/08/2023 Q1 -- -- -$0.58 -- --
03/15/2023 Q4 -- -- -$0.60 -- --
11/14/2022 Q3 -- -- -$0.63 -- --
08/09/2022 Q2 -- -- -$0.58 -- --
05/10/2022 Q1 -- -- -$0.63 -- --
03/16/2022 Q4 -- -- -$0.69 -- --
11/12/2021 Q3 -- -- -$0.65 -- --
08/12/2021 Q2 -- -- -$0.57 -- --
05/11/2021 Q1 -- -- -$0.46 -- --
03/16/2021 Q4 -- -- -$0.44 -- --
11/10/2020 Q3 -- -- -$0.38 -- --
06/30/2020 Q2 -- -- -$0.26 -- --
03/31/2020 Q1 -- -- -$0.22 -- --
12/31/2019 Q4 -- -- -$0.23 -- --
09/30/2019 Q3 -- -- -$0.15 -- --

Prelude Therapeutics, Inc. Earnings Questions

  • How Much did Prelude Therapeutics, Inc. Generate in Revenue Last Quarter?

    Prelude Therapeutics, Inc. reported $6.5M worth of top line sales in its most recent quarter.

  • Did Prelude Therapeutics, Inc. Beat Earnings Last Quarter?

    Prelude Therapeutics, Inc. announced earnings per share of -$0.26 which represents a beat of analyst forecast a -$0.36 per share.

  • Is Prelude Therapeutics, Inc. Profitable?

    Prelude Therapeutics, Inc. reported $6.1M that represents $0.08 per share over the last quarter.

  • What is the Analyst Consensus for Prelude Therapeutics, Inc. EPS Next Year?

    Prelude Therapeutics, Inc.'s earnings are forecast to decrease from -$1.68 per share to -$1.27 per share next year representing a decrease of -24.3%.

  • When is Prelude Therapeutics, Inc.'s Earnings Date?

    Prelude Therapeutics, Inc.'s next earnings date is March 17, 2026.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is DocuSign Stock Undervalued?
Is DocuSign Stock Undervalued?

Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…

Is SentinelOne Stock Undervalued?
Is SentinelOne Stock Undervalued?

Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…

Is Broadcom Stock on Sale?
Is Broadcom Stock on Sale?

Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…

Stock Ideas

Buy
59
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 65x

Buy
55
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
72
GLTO alert for Dec 27

Galecto, Inc. [GLTO] is up 16.92% over the past day.

Sell
20
SMX alert for Dec 27

SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.

Sell
11
CDNAF alert for Dec 27

Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock